Values of molecular markers in the differential diagnosis of thyroid abnormalities T. M. P. B. TennakoonM. RushdhiR. S. Dassanayake Review – Cancer Research 22 December 2016 Pages: 913 - 931
Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells Yoichi IwamotoKenichiro IshiiYoshiki Sugimura Original Article – Cancer Research 27 February 2017 Pages: 933 - 939
Ferritin heavy chain as a molecular imaging reporter gene in glioma xenografts Sen ChengRuifang MiFusheng Liu Original Article – Cancer Research 28 February 2017 Pages: 941 - 951
Genetic and epigenetic patterns in patients with the head-and-neck paragangliomas associate with differential clinical characteristics Hongsai ChenWeidong ZhuHao Wu Original Article – Cancer Research 03 March 2017 Pages: 953 - 960
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib Marjut NiinivirtaGunilla EnbladGustav J. Ullenhag Original Article – Cancer Research Open access 04 March 2017 Pages: 961 - 970
Phosphorylase kinase β affects colorectal cancer cell growth and represents a novel prognostic biomarker Guanghui WangWenbin ShenLong Cui Original Article – Cancer Research 08 March 2017 Pages: 971 - 980
Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression Ji-Nan XiaoTing-Hua YanJin-Hua Jiang Original Article – Cancer Research 08 March 2017 Pages: 981 - 990
Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression Lei PanWei LiangXu Zhang Original Article – Cancer Research 11 March 2017 Pages: 991 - 1004
The effects of microRNAs on glucocorticoid responsiveness Huimin WangXuxu GouJuan Ouyang Review – Clinical Oncology 12 March 2017 Pages: 1005 - 1011
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy Qian JiangHai-Bo WangRobert Peter Gale Original Article – Clinical Oncology 01 March 2017 Pages: 1013 - 1022
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care Carl Christoph SchimanskiFrank StaibMarkus Moehler Original Article – Clinical Oncology 14 February 2017 Pages: 1023 - 1034
The presence of cancerous nodules in lymph nodes is a novel indicator of distant metastasis and poor survival in patients with papillary thyroid carcinoma Ling ChenYouzhi ZhuXiangjin Chen Original Article – Clinical Oncology 15 February 2017 Pages: 1035 - 1042
Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma ≤3 cm with wedge resection Yiyang WangRui WangHaiquan Chen Original Article – Clinical Oncology 15 February 2017 Pages: 1043 - 1051
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer Takuji OkusakaH. Miyakawaon behalf of the GEST group Original Article – Clinical Oncology Open access 16 February 2017 Pages: 1053 - 1059
Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma Yue ZhaoAnnelore Altendorf-HofmannThomas Knösel Original Article – Clinical Oncology 17 February 2017 Pages: 1061 - 1068
Impact of prior breast cancer on mode of delivery and pregnancy-associated disorders: a retrospective analysis of subsequent pregnancy outcomes Louis JacobMatthias KalderKarel Kostev Original Article – Clinical Oncology 20 February 2017 Pages: 1069 - 1074
Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases Hibiki UdagawaSeiji NihoKoichi Goto Original Article – Clinical Oncology 20 February 2017 Pages: 1075 - 1082
Clinical impact of sarcopenia and relevance of nutritional intake in patients before and after allogeneic hematopoietic stem cell transplantation Shouichi TanakaOsamu ImatakiTetsuji Yamamoto Original Article – Clinical Oncology 21 February 2017 Pages: 1083 - 1092
The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location Lele SongJia JiaYuemin Li Original Article – Clinical Oncology 21 February 2017 Pages: 1093 - 1101
Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report Sienkiewicz BeataUrbaniak-Kujda DonataWiela-Hojeńska Anna Original Article – Clinical Oncology Open access 28 February 2017 Pages: 1103 - 1106